Proud contributor to public health
Navamedic is a nordic pharma company and a reliable supplier of high-quality products.
29.12.2025
Grete Roede og Navamedic lanserer nytt vektreduksjonskonsept: Lettere steg
12.12.2025
Navamedic ASA: Notice of extraordinary general meeting on 7 January 2026
09.12.2025
Oslo, December 9, 2025 – Navamedic ASA Introduces Flexilev[®] in OraFID[®]: Enhancing Parkinson’s Care with Simplified and Precise Dosing for Personalized Treatment
-
Employees
43
-
Revenue 2024 (MNOK)
531.4
-
EBITDA 2024 (MNOK)
46.6
-
Number of products
84
-
Countries where products are sold
13
-
Established in
2002
Financial Results
Take part of up-to-date financial results in our quarterly webcasts and reports.
View results
Enhanced Parkinson Care
Navamedic introduces a groundbreaking advancement in Parkinson’s care, enhancing precision and personalization in treatment. Our latest innovation aims to improve patient outcomes by addressing individual needs through simplified dosing.
Learn more